Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
57.31
-0.85 (-1.46%)
At close: Feb 6, 2026
SHA:600276 Revenue
Jiangsu Hengrui Pharmaceuticals Co.,Ltd had revenue of 7.43B CNY in the quarter ending September 30, 2025, with 12.72% growth. This brings the company's revenue in the last twelve months to 30.98B, up 19.19% year-over-year. In the year 2024, Jiangsu Hengrui Pharmaceuticals Co.,Ltd had annual revenue of 27.98B with 22.63% growth.
Revenue (ttm)
30.98B
Revenue Growth
+19.19%
P/S Ratio
12.27
Revenue / Employee
1.53M
Employees
20,238
Market Cap
380.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
| Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
| Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
| Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
| Dec 31, 2020 | 27.73B | 4.45B | 19.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 43.09B |
| Yunnan Baiyao Group Co.,Ltd | 40.77B |
| Shanghai Fosun Pharmaceutical (Group) | 39.55B |
| China Resources Sanjiu Medical & Pharmaceutical | 29.86B |
| Humanwell Healthcare (Group) | 24.18B |
| Zhejiang NHU Company | 22.47B |
| Beijing Tongrentang | 18.09B |
| Changchun High-Tech Industry (Group) | 12.88B |